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Abstract 
Purpose: Circulating microRNAs (miRNA) have been described in patients with 
adrenocortical tumors, but the expression of miRNAs in non-functioning and cortisol-
producing tumors has not been yet compared. Therefore, the objective of this study was to 
evaluate the expression of plasma extracellular vesicle (EV)-associated microRNAs in 
patients with non-functioning adrenocortical adenoma (NFA), cortisol-producing 
adrenocortical adenoma (CPA) and cortisol-producing adrenocortical carcinoma (CP-ACC). 
Methods: Preoperative plasma EV samples of 13 NFAs, 13 CPAs and 9 CP-ACCs were 
subjected to extracellular vesicle isolation. miRNAs were investigated by targeted quantitative 
real-time PCR normalized to cel-miR-39 as reference. Five miRNAs have been selected for 
this analysis based on previous studies including hsa-miR-22-3p, hsa-miR-27a-3p, hsa-miR-
210-3p, hsa-miR-320b and hsa-miR-375.  
Results: We have observed significant overrepresentation of 3 miRNAs in both CPA and CP-
ACC relative to NFA: hsa-miR-22-3p (p<0.01 and p<0.0001, respectively), hsa-miR-27a-3p 
(p<0.05 in both comparisons) and hsa-miR-320b (p<0.05 and p<0.0001, respectively). Hsa-
miR-320b has been significantly overrepresented in CP-ACC relative to CPA (p<0.01). Hsa-
miR-210-3p turned out to be significantly overrepresented only in CP-ACC compared to NFA 
(p<0.05). Significant correlation was revealed between circulating miRNA concentrations and 
urinary free cortisol values for hsa-miR-22-3p, hsa-miR-27a-3p and hsa-miR-320b (p<0.0001 
for all) and cortisol after low dose dexamethasone test for hsa-miR-22-3p and hsa-miR-320b 
(p<0.05). Hsa-miR-27a-3p has been significantly stimulated by low dose dexamethasone test 
(p<0.05). 
Conclusions: EV-associated miRNAs are differentially expressed in different non-
functioning and cortisol-producing adrenocortical tumors.  
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Introduction 
Adrenocortical tumors are frequent, and their prevalence increases with age reaching around 
10 % in the elderly in radiological series with peaks in the 5.-7. decades [1]. The vast majority 
of these tumors are represented by benign adrenocortical adenomas (ACA). The most 
common ACAs are clinically silent non-functioning adenomas (NFAs) [2]. In contrast, 
cortisol-producing adenomas (CPAs) result in serious morbidity and mortality associated with 
Cushing’s syndrome [3][4]. Adrenocortical carcinoma (ACCs) is a rare (incidence 0.5-
2/million/year), but aggressive tumor with poor prognosis in advanced stages [5]. In more 
than 80% of ACCs autonomous hormone production (mainly cortisol) is observed [6]. 
MicroRNAs (miRNAs) are small, non-protein coding RNA molecules that are 16-24 
nucleotides long in their single-stranded mature form. More than 50 % of protein-coding 
human genes are predicted to be modulated by miRNAs [7]. MiRNAs, as epigenetic 
regulators are involved mainly in the post-transcriptional regulation of gene expression [7].  
MiRNAs are found not only in tissues, but also in body fluids [8]. MiRNAs in the 
circulation are in part packed in actively secreted extracellular vesicles (EV) (exosomes, 
microvesicles, apoptotic bodies) that render them very stable [9]. Several studies (including 
ours) demonstrated significantly differential expression of miRNAs in benign and malignant 
adrenocortical tumors, both in tissue samples and blood [3][10][11][12][13]. Blood-borne 
(plasma or serum) circulating miRNAs could be minimally invasive biomarkers of 
adrenocortical malignancy as a form of liquid biopsy [10][13][14]. We have found higher 
diagnostic sensitivity and specificity of miRNAs isolated from EVs [14], than miRNAs 
isolated from whole plasma [13].  
 The expression of tissue miRNAs is different between hormonally active and inactive 
adrenocortical tumors [15], but the expression of circulating miRNAs in non-functioning and 
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cortisol-producing tumors has not been studied, yet. On the other hand, the expression of 
miRNAs appears to be modulated by hormones. In our previous study, adrenocorticotropin 
and dexamethasone were found to affect the expression of circulating hsa-miR-27a-3p [16]. 
The objective of this study was to evaluate the expression of EV-associated miRNAs in 
patients suffering from NFA, CPA and cortisol-producing ACCs (CP-ACC). Since urinary 
steroid metabolomics studies show that the vast majority of ACC, even the clinically 
hormonally inactive, secrete steroid hormones or their precursors [17][18], we have studied 
only ACC with manifest Cushing’s syndrome.  
 
Materials and methods 
Patients’ samples 
Altogether 35 preoperative plasma samples were collected from patients with NFA (n=13), 
CPA (n=13) and CP-ACC (n=9). The hormonal profile was examined in all cases, and the 
diagnosis of hypercortisolism was based on current guidelines [4]. In the CPA and CP-ACC 
groups, we have included only patients having overt Cushing’s syndrome. The diagnosis of 
ACA or ACC was determined by histological investigation in operated cases, whereas the 
diagnosis of non-operated ACAs was based on imaging and follow-up by abdominal 
computed tomography. The ENSAT (European Network for the Study of Adrenal Tumors) 
criteria system was used to determine the tumor stage in ACC [19]. The clinical 
characteristics of the three cohorts are summarized in Table 1. No chemo- or radiotherapy 
was applied in ACC-patients prior to blood collection. 
We have also reanalyzed 7 plasma sample pairs from our previous study in individuals 
with normally functioning hypothalamo-pituitary-adrenal axis before and after low dose (1 
mg) overnight dexamethasone test (LDDT) [16]. 
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The Ethical Committee of the Hungarian Health Council endorsed these studies. 
Informed consent was acquired from every patient involved.  
 
Extracellular vesicle and RNA isolation  
EDTA-anticoagulated blood was collected from patients and processed for plasma isolation 
instantly after blood taking. Plasma was gained by centrifuging whole blood at 1000xg for 10 
minutes at 4 
o
C. All extracted plasma samples were stored at -80 
o
C until further application. 
EVs were isolated from 200 µl plasma with Total Exosome Isolation (from plasma) Kit 
(Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol.  
Total RNA was immediately extracted from EVs using Total Exosome RNA and 
Protein Isolation Kit (Thermo Fisher Scientific). 5 µl of 5 nM Syn-cel-mir-39 miScript 
miRNA Mimic (Qiagen GmbH) was added before the addition of Acid-Phenol: Chloroform. 
The final total RNA elute was 50 µl and was stored at -70 oC until further use. 
 
Analysis of miRNA expression by quantitative RT-PCR 
The analysis of miRNA expression of EVs was performed using real-time qPCR. Five 
miRNAs (hsa-miR-22-3p (000398), hsa-miR-27a -3p (000408), hsa-miR-210-3p (000512), 
hsa-miR-320b (002844) and hsa-miR-375 (000564)) were studied. For data normalization, 
cel-miR-39 (000200) was used as reference. 
Total RNA (5 µl) was reverse transcribed using specific TaqMan microRNA Assays 
(PN 442795, Thermo Fisher Scientific) and the TaqMan MicroRNA Reverse Transcription 
Kit (Thermo Fisher Scientific) on Proflex Base PCR System (Thermo Fisher Scientific). RT-
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qPCR was performed by TaqMan Fast Universal PCR Master Mix (2x) (PN: 4352042, 
Thermo Fisher Scientific) on QuantStudio 7 Flex Real-Time PCR system (Thermo Fisher 
Scientific) according to the manufacturer’s protocol (PN 4364031E, Thermo Fisher Scientific) 
with minor modifications (the maximum allowed CT value was set to 40). Samples were run 
in triplicate. Negative control reactions did not include cDNA templates 
 
Statistical analysis  
Statistical analysis of data was performed by GraphPad Prism 7.02 (GraphPad Software, Inc., 
La Jolla, CA, USA). For the identification of differentially expressed miRNAs between the 
three groups, one-way ANOVA followed by Tukey’s post Hoc test or Kruskal-Wallis test 
followed by Dunn test were used based on the results of Shapiro-Wilk normality test.  
For data analysis, we used the -dCT (CT) method (-dCT values= - [-CT of target miRNA– -
CT of internal control miRNA]) using GraphPad Prism 7.02. Correlation of basal morning 
cortisol levels, 24 h urinary free cortisol (UFC) and cortisol after LDDT(C-LDDT) and 
miRNA -dCT values were performed by Spearman correlation assay. Receiver operating 
characteristics (ROC) analysis was performed to test the diagnostic applicability of hsa-miR-
320b between CPA and CP-ACC. For the evaluation of miRNA expression in response to 
LDDT, unpaired t-test was performed after Shapiro-Wilk normality test. 
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Results 
EV-associated miRNA expression analysis of different adrenocortical tumor subtypes by 
RT-qPCR  
35 preoperative plasma samples were evaluated by RT-qPCR analysis in order to identify 
differences in circulating EV-associated miRNA expression of different subtypes of 
adrenocortical tumors. RT-qPCR appears to be the most appropriate method to quantify the 
expression of extracellular miRNAs [20]. Based on previous studies, we chose to include 
altogether 5 human miRNAs [15][16]. The widely used synthetic spike-in control RNA cel-
miR-39 was applied as reference [21].
 
 
We have observed significant underrepresentation of hsa-miR-22-3p in NFA 
compared with CPA (fold change (FC) 3.21) (p<0.01), and NFA relative to CP-ACC (FC= 
7.34) (p<0.0001). We could not detect significant differences in its expression between CPA 
compared to ACC (Figure 1a). Hsa-miR-27a-3p was underrepresented in NFA relative to 
both CPA (FC=3.55) and CP-ACC (FC=4.59) (p<0.05) (Figure1b). We have found 
significantly higher expression of hsa-miR-320b in CP-ACC (FC=10.88) and CPA (FC=2.57) 
relative to NFA (p<0.0001, and p<0.05, respectively). Moreover, the expression of hsa-miR-
320b was significantly overrepresented in CP-ACC versus CPA (p<0.01) (Figure 1c). ROC 
analysis revealed an AUC of 0.8632 (sensitivity: 88.89 %, specificity: 76.92 %) for the 
differentiation of CP-ACC and CPA by hsa-miR-320b. Hsa-miR-210-3p was significantly 
overrepresented only in the CP-ACC (FC=3.1) vs NFA comparison (Figure 1d). Hsa-miR-
375 showed no difference among different tumor types (Supplementary Figure 1.). Raw RT-
qPCR data are presented in Supplementary Table 1. There were no differences in miRNA 
expression between males and females of the CP-ACC group. 
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Regarding the correlation of cortisol parameters to circulating miRNA levels (-dCT), 
we have observed no correlation with basal cortisol levels, but UFC levels were significantly 
correlated with circulating hsa-miR-22-3p, hsa-miR-27a-3p and hsa-miR-320b (p<0.0001 for 
all) (Figures 1e-g). C-LDDT concentrations were significantly associated with hsa-miR-22-
3p (p=0.0216) and hsa-miR-320b (p=0.0237) (Supplementary Table 2.). 
Hsa-miR-22-3p, hsa-miR-27a-3p and hsa-miR-320b have been reanalyzed in sample 
pairs of our previous study on miRNA levels before and after LDDT. EV-associated hsa-miR-
27a-3p has been significantly stimulated by 1 mg dexamethasone, whereas a tendency not 
reaching significance could be observed for hsa-miR-320b and hsa-miR-22-3p  (Figure 1h). 
 
Discussion 
Here, we report the overrepresentation of three circulating, EV-associated miRNAs in 
cortisol-producing adrenocortical tumors relative to non-functioning adenomas. The five 
miRNAs tested were selected based on three previous studies. Expression of hsa-miR-27a-3p 
was found to be stimulated by LDDT in our previous study [16]. We have chosen hsa-miR-
22-3p and hsa-miR-320b from the study of Velazquez-Fernandez et al. on the expression of 
tissue miRNAs in ACA: hsa-miR-22-3p was the most overexpressed miRNA in CPA relative 
to normal tissue, whereas hsa-miR-320b was among the most overexpressed miRNAs in CPA 
vs. NFA [15]. Hsa-miR-210-3p and hsa-miR-375 were included as these were significantly 
differentially expressed in CPA and ACC in our previous study on tissue miRNAs [11]. We 
have found only one miRNA (hsa-miR-320b) to be significantly differentially expressed 
between CPA and CP-ACC, while the expression of the other three miRNAs was similar in 
benign and malignant cortisol-producing tumors. Hsa-miR-210-3p was only significantly 
overrepresented in CP-ACC relative to NFA, but not in CPA, thus it cannot be regarded as a 
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miRNA associated to cortisol-producing tumors, rather a marker of malignancy. In fact, hsa-
miR-210 is the major hypoxamiR that has been shown to be overexpressed in several 
malignant tumors, including ACC [11][22][23]. 
Based on our previous studies on the diagnostic applicability of circulating miRNAs 
for adrenocortical malignancy isolated from whole plasma or from EVs, we have concluded 
that EV-derived miRNAs could be more sensitive and specific than miRNAs isolated from the 
whole plasma [13][14]. We have used the same protocol as in our latest study, where the kit 
used for exosome isolation has been verified as reliable by a parallel ultracentrifugation-based 
protocol including analysis of EV size distribution, and flow cytometry analysis of membrane 
markers [14], thus the miRNAs tested can be regarded as EV-associated. 
As there is no generally accepted reference gene for raw data normalization in 
extracellular miRNAs studies [21], we have used the widely used synthetic spike-in control 
RNA cel-miR-39 as reference gene for data normalization as in our previous study [14]. 
No difference of miRNA expression between males and females of CP-ACC group 
was noted, and there are no data that the EV miRNA content in tumors would be affected by 
sex, thus the relative underrepresentation of males in NFA and CPA cohorts relative to CP-
ACC is biologically probably irrelevant. 
The cellular origin of miRNAs overrepresented in cortisol-producing adrenocortical 
tumor patients is unknown. Their relative abundance in hypercortisolemic patients might raise 
the possibility that oversecreted glucocorticoids might play a role in their overrepresentation. 
Our observation that the expression of three of four miRNAs has been the same between 
cortisol producing adrenocortical adenomas and carcinomas, might also argue for the 
relevance of hormonal action on the observed miRNA expression differences instead of 
expression changes related to tumor malignancy. In our previous study describing the 
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hormonal modulation of hsa-miR-27a-3p, we localized a glucocorticoid response element 
(GRE) within the promoter region of hsa-miR-27a-3p by in silico prediction [16]. Now, we 
could identify a potential GRE within the promoter of hsa-miR-22-3p and hsa-miR-320b, but 
not in hsa-miR-210-3p (TFBIND software, http://tfbind.hgc.jp). Thus, it can be assumed that 
hypercortisolism might be implicated in the overrepresentation of these miRNAs. This 
hypothesis appears to be supported by our observation that LDDT significantly stimulates 
EV-associated hsa-miR-27a-3p. Moreover, significant correlation with UFC was found for 
hsa-miR-22-3p, hsa-miR-27a-3p and hsa-miR-320b, and with C-LDDT for hsa-miR-22-3p 
and hsa-miR-320b that also support the link between these miRNAs and cortisol. 
Hsa-miR-27a-3p appears to be involved in several physiological and pathological 
conditions such as: angiogenesis, obesity, immune functioning, atherosclerosis, insulin 
resistance and type 2 diabetes mellitus (DM) [24]. Hsa-miR-22-3p impaired gluconeogenesis 
and enhanced hepatic glucose production [25]. Hsa-miR-320b was also implicated in the 
pathogenesis of type 2 DM [26]. It might even be possible that these miRNAs might have 
some role in the insulin resistance and diabetes of patients suffering from Cushing’s 
syndrome. All overrepresented miRNAs have been associated to different tumors 
[27][28][29], but except for hsa-miR-210-3p, there are no data yet on their altered expression 
in adrenocortical malignancy [11][22].  
In conclusion, our results show that EV-associated miRNAs are differentially 
expressed in non-functioning benign and cortisol-producing adrenocortical tumors. We 
hypothesize that hypercortisolism might be implicated in the overrepresentation of three of 
these miRNAs.  
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Figure legends 
Figure 1 
Results of RT-qPCR analysis of (a) hsa-miR-22-3p; (b) hsa-miR-27a-3p; (c) hsa-miR-320b; 
normalized to the spike-in control cel-miR-39, mean±SD, *p <0.05 **p < 0.01, ***p< 0.001, 
****p< 0.0001; n= 13 NFA, n= 13 CPA, n=9 CP-ACC, (One-way ANOVA followed by 
Tukey’s post Hoc test.)  
(d) Results of RT-qPCR analysis of hsa-miR-210-3p normalized to cel-miR-39, mean±SD   
*p <0.05, n= 12 NFA, n= 13 CPA, n=9 CP-ACC, (Kruskal-Wallis test followed by Dunn’s 
multiple comparisons test)  
Correlation between urinary free cortisol (nmol/24h) and expression of miRNAs (-dCT) for 
(e) hsa-miR-22-3p, (f) hsa-miR-27a-3p and (g) hsa-miR-320b, p<0.0001 n=22, Spearman 
rank correlation was used after Shapiro-Wilk normality test. 
(h) Expression change (-dCT) of hsa-miR-22-3p, hsa-miR-27a-3p and hsa-miR-320b before 
and after low dose (1mg) dexamethasone suppression test in individuals having no 
abnormality of the hypothalamo-pituitary-adrenal axis normalized to cel-miR-39 mean±SD, 
*p <0.05, n=7, unpaired t-test was performed following the Shapiro-Wilk normality test. 
White boxes represent values before dexamethasone, grey boxes after dexamethasone 
administration. 
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Table 1 
Characteristics of patients 
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1 NFA F 56 
Non-
functioning 
   
440.6 n.d. 52.3 
2 NFA F 58 
Non-
functioning 
   
494.14 n.d. 212.4 
3 NFA F 66 
Non-
functioning 
   
361.98 42.21 16.8 
4 NFA F 81 
Non-
functioning 
   
579.39 n.d. n.d. 
5 NFA M 54 
Non-
functioning 
   
256.6 19 n.d. 
6 NFA F 73 
Non-
functioning 
   
381 n.d. n.d. 
7 NFA F 52 
Non-
functioning 
   
400 n.d. 97 
8 NFA F 63 
Non-
functioning 
   
217 n.d. n.d. 
9 NFA F 38 
Non-
functioning 
   
163.82 41 413.85 
10 NFA F 60 
Non-
functioning 
   
358.67 39 206.925 
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11 NFA M 50 
Non-
functioning 
   
609 38 n.d. 
12 NFA F 35 
Non-
functioning 
   
n.d. n.d. n.d. 
13 NFA F 65 
Non-
functioning 
   
n.d. n.d. 188 
14 CPA F 37 Cortisol    
200.9 316.45 1387 
15 CPA F 61 Cortisol    
474.8 252.17 75.3 
16 CPA F 50 Cortisol    
623.3 673.19 1022 
17 CPA M 62 Cortisol    
676 n.d. 974 
18 CPA F 59 Cortisol    
579.39 524 386.26 
19 CPA F 62 Cortisol    
689.75 690 7007.86 
20 CPA F 51 Cortisol    
275.9 n.d. 1682.99 
21 CPA F 55 Cortisol    
n.d. n.d. 1347 
22 CPA F 24 Cortisol    
1114 510 220 
23 CPA F 43 Cortisol    
420 n.d. n.d. 
24 CPA F 47 Cortisol    
n.d. 361.4 589 
25 CPA F 27 Cortisol    
954 n.d. n.d. 
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26 CPA F 69 Cortisol    n.d. 103.6 n.d. 
27 
CP-
ACC 
F 67 Cortisol n.d. n.d. 4 1771.3 1561.5 3235.1 
28 
CP-
ACC 
F 36 Cortisol n.d. n.d. 4 3233.51 n.d. 15612 
29 
CP-
ACC 
F 51 Cortisol 25 9 3 742 141 n.d. 
30 
CP-
ACC 
M 62 Cortisol 30 7 2 693 796 n.d. 
31 
CP-
ACC 
M 48 Cortisol 15 8 3 728 n.d. n.d. 
32 
CP-
ACC 
F 38 Cortisol 70 8 2 411 n.d. n.d. 
33 
CP-
ACC 
M 58 Cortisol 30 n.d. 2 672.6 n.d. 2277.6 
34 
CP-
ACC 
F 64 Cortisol 30 5 4 1491 n.d. 10743 
35 
CP-
ACC 
M 68 Cortisol n.d. n.d. 1 364.5 394.81 8795 
 
n.d.: no data, F: female, M: male, C-LDDT: cortisol after low dose dexamethasone test, UFC: 
24 h urinary free cortisol 
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Supplementary Tables 
 
Supplementary Table 1. 
Raw data of the RT-qPCR analyses. 
 
Supplementary Table 2 
Spearman correlation analysis of cortisol parameters (basal morning cortisol, 24 h urinary free 
cortisol and cortisol after low-dose dexamethasone test) with miRNA –dCT values. Fold 
change and –dCT values for RT-qPCR analyses. 
 
Supplementary Figure 1. 
Results of RT-qPCR analysis for hsa-miR-375 
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Fig. 1. 
 
